The recognition of LY6E as a promising target for cancer treatment has driven considerable investigation . Various antibody agents are being tested with the purpose of directly neutralizing LY6E's function and inducing an therapeutic response in patients suffering with differing tumors. Challenges remain in optimizing therapeutic delivery and addre